Anti-VEGF: Looking Forward in Lung Cancer
References
  1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006.
  2. Herbst RS, Prager D, Hermann, R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemo- therapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-9.
  3. Sandler AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355:2542-50.
  4. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. J Clin Oncol 2006; 24:abstract 7001.
  5. Lorusso PM, Heath E, Valdivieso M, et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006; 24(18S):3034.
  6. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006; 24:abstract 7002.
  7. Gatzemeier U. Slides presented at ASCO 2006 Annual Meeting. Session: Antiangiogenesis inhibitors in lung cancer (Clinical Science Symposium).
  8. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007; 67:2729-35.
  9. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angio- genesis, and tumor growth following oral administration. Cancer Res 2002; 62:4646-55.
  10. Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J Clin Oncol 2006; 24(18S):7000.
  11. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
  12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64.
  13. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
  14. Gimbrone MA Jr, Leapman SB, Cotran RS, et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136:261-76.
  15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
  16. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 29:(6 suppl 16):3-9.
  17. Kaban K, Herbst R. Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am 2002; 16:1125-71.
  18. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62.
  19. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5:1359-64.
  20. Asano M, Yukita A, Matsumoto T, et al. Inhibition of tumor-growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor vascular permeability factor. Cancer Res 1995; 55:5296-301.
  21. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-4.
  22. Stefanou D, Goussia AC, Arkoumani E, et al. Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non-small cell lung cancer. Anticancer Res 2003; 23:4715-20.
  23. Oshika Y, Nakamura M, Tokunaga T, et al. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 1998; 12:541-4.
  24. Fontanini G, Boldrini L, Chine S, et al. Expression of vascular endothelial growth factor mRNA in non-small cell lung carcinomas. Br J Cancer 1999; 79:363-9.
  25. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27.
  26. O'Bryne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial growth factor and angiogenesis in non-small cell lung cancer. Br J Cancer 2000; 82:1427-32.
  27. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89:881-6.
  28. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small cell lung cancer. J Clin Oncol 2001; 19:432-41.
  29. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2000; 8:72-9.
  30. Takahashi H, Shibuy M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiologic and pathologic conditions. Clin Sci 2005; 109:227-41.
  31. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-39.
  32. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380:439-42.
  33. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: a new frontier in metastasis research. Nat Cell Biol 2002; 4:E2-5.
  34. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
  35. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23:abstract 2.
  36. Schiller J, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
  37. Brahmer JR, Gray R, Schiller JH, et al. ECOG 4599 phase III trial of carboplatin and paclitaxel ± bevacizumab: subset analysis of survival by gender. J Clin Oncol 2006; 24:abstract 7036.
  38. Kraut M. Phase II study of gemcitabine and carboplatin plus bevacizumab for stage III/IV non-small cell lung cancer: preliminary safety data. J Clin Oncol 2006; 24:abstract 17091.
  39. Somer R, Langer CJ, Millenson M, et al. Restrictive eligibility criteria may limit applicability of new therapies in NSCLC. Proc Am Soc Clin Oncol. 2003; 22:abstract 2687.
  40. Patel JD, Hensing TA, O'Keeffe P, et al. Pemetrexed and carboplatin plus beva- cizumab as first-line therapy for advanced non-squamous non-smallcell lung cancer: preliminary safety results of a phase II trial. J Clin Oncol 2006;24:abstract 17111.
  41. Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC). Ann Oncol 2006; 17: abstract 729PD.
  42. Blumenschein G, Sandler A, O'Rourke T, et al. Safety and pharmacokinetics (PK) or AMG706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of pts. with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24: abstract 7119.
  43. Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. J Clin Oncol 2006; 24:abstract 7016.
  44. Laurie SA, Arnold A, Gauthier I, et al. Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). J Clin Oncol 2006; 24:abstract 3054.
  45. Schiller JH, Flaherty KT, Redlinger M, et al.Sorafenib combined with carboplatin/ paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. J Clin Oncol 2006 ;24:abstract 7194.
  46. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37.
  47. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109.
  48. Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 2003; 9:866–71.
  49. Tortora G, Caputo R, Damiano V, et al. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic and anti-angiogenic activity. Clin Cancer Res 2003; 9:1566-72.
  50. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-47.
  51. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001; 85:584-9.
  52. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38:1133-40.
  53. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7:1459-65.
  54. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-60.
  55. Morelli MP, Cascone T, Troiani T, et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 2006; 208:344-53.
  56. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
  57. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37.
  58. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cis platin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22(14S):abstract 7010.
  59. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 2004; 22:777–84.
  60. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 2004; 22:785-94.
  61. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005; 23:8646
  62. Vokes EE, Cohen AM, Mauer TG, et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 2005; 23(16S):5504.
  63. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-55.
  64. Van Cruijsen H, Voest EE, Van Herpen CM, et al. Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. Available online Accessed April 5, 2007.
  65. Adjei AA, Mandrekar S, Marks RS, et al. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:(206S):abstract 3067.
  66. Fehrenbacher L, O'Neill V, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2006; 24(18S):7062.
  67. Azad NS, Posadas EM, Kwitkowski VE, et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol, 2006; 24(18S):3004.
  68. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9:1546-56.
  69. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284-90.
  70. Williams KJ, Telfer BA, Stratford IJ, et al. Schedule-dependent effects of ZD6474, a potent inhibitor of VEGF signaling, combined with radiotherapy in a lung tumor xenograft model. Clin Cancer Res 2003; 9:6141S.
  71. Hurwitz H, Holden SN, Eckhardt SG, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signalling, in patients with solid tumors. Proc Am Soc Clin Oncol 2002; 21:82a.
  72. Minami H, Ebi H, Tahara M, et al. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 2003; 22:194.
  73. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005; 23(16S):3002.
  74. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376:66-70.